LINOR 2 mg/ml Price

Overview

Welcome to Dwaey, specifically on LINOR 2 mg/ml Solution for infusion page.
This medicine contains an important and useful components, as it consists of Linezolid.
LINOR 2 mg/ml is available in the market in concentration 2 mg/ml and in the form of Solution for infusion.

LABORATORIOS NORMON ,S.A. is the producer of LINOR 2 mg/ml and it is imported from SPAIN, The most popular alternatives of LINOR 2 mg/ml are listed downward .

Mode Of Action

Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria.

Indication

• Community-acquired pneumonia
• Skin and skin structure infections
• Nosocomial pneumonia

Precaution

Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis. Lactation: Unknown; use caution

Side Effects

• >10% Pediatrics Diarrhea (7.8-10.8%) 1-10% Headache (5.7-8.8%).Diarrhea (8.2-8.3%)
• Nausea (5.1-6.6%)
• Vomiting (2-4.3%)
• Dizziness (1.8-2.6%)
• Rash (1.1-2.3%)
• Vaginal moniliasis (1.1-1.8%)
• Taste alteration (1-1.8%)
• Oral moniliasis (0.5-1.7%)
• Abnormal LFTs (0.4-1.6%)
• Fungal infection (0.3-1.5%)
• Localized abdominal pain (1.2-1.3%)
• Tongue discoloration (0.3-1.3%)
• Generalized abdominal pain (0.9-1.2%) Pediatrics Vomiting (2.9-9.4%)
• Headache (0.9-6.5%)
• Anemia (5.6%)
• Thrombocytopenia (4.7%)
• Nausea (1.9-3.7%)
• Generalized abdominal pain (0.9-2.4%)
• Localized abdominal pain (0.5-2.4%)
• Loose stools (1.6-2.3%)
• Eosinophilia (0.4-1.9%)
• Pruritus
• other than application site (0.8-1.4%)
• Vertigo (1.2%) <1% Lactic acidosis
• Myelosuppression
• Peripheral neuropathy
• Disorder of optic nerve
• Serotonin syndrome Potentially Fatal: Reversible myelosuppression including anaemia
• leukopenia
• pancytopenia and thrombocytopenia (particularly if using > 10-14 days)
• transient ischaemic attacks
• renal failure
• Stevens-Johnson syndrome.

Contra indication

Linzolid formulations are contraindicated for use in patients who have known hypersensitivity to Linzolid or any of the other product components. Linzolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. Linzolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome and/or patients taking directly and indirectly acting sympathomimetic agents (e.g. pseudoephedrine), vasopressive agents (e.g. epinephrine, norepinephrine), dopaminergic agents (e.g. dopamine, dobutamine), serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks